# Kamui Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kamui-pharma

- Industry: Pharmaceuticals
- Headquarters: Asahikawa, Japan
- Website: www.kamuipharma.co.jp/
- Total disclosed funding: $6.8M
- Latest round: Series B (Jul 26, 2022)
- Investors on record: 4

## About

Based in Japan, Kamui Pharma, Inc. operates as a biopharmaceutical company focused on developing probiotic medicines aimed at addressing health challenges related to the gut microbiome.Kamui Pharma, Inc., founded in 2018 and headquartered in Asahikawa, Japan, specializes in probiotic medicines derived from research at Asahikawa Medical University. The company has completed 2 significant deals, with its most recent funding round being a Series B in July 2022, raising JPY 650 million from investors including CEJ Capital and Mitsubishi UFJ Capital. The total amount raised by Kamui Pharma is JPY 650 million, and its current valuation stands at JPY 2,113.412 million.Kamui Pharma, Inc. specializes in the development of probiotic medicines, leveraging cutting-edge research from its roots at Asahikawa Medical University. The company's primary offerings are designed to address various health challenges through the modulation of the gut microbiome. These products aim to enhance gastrointestinal health and overall well-being, targeting conditions typically associated with digestive disorders and immune system support. Kamui Pharma focuses on both clinical applications and consumer health products, catering to a diverse clientele that includes healthcare professionals, hospitals, and individual consumers. The company is actively pursuing markets within Japan and potentially expanding into selected international markets as regulatory approvals and partnerships develop.The revenue model of Kamui Pharma is structured around B2B partnerships and direct-to-consumer sales, reflecting a dual approach that optimizes market reach. The company engages in transactions with hospitals and healthcare facilities, offering subscription-based access to proprietary probiotic formulations or engaging in wholesale agreements for bulk purchases. Pricing structures are tailored to various customer segments, ensuring accessibility while reflecting the value of the innovative products offered. While specific pricing details for flagship products are not publicly available, the company's revenue strategy is designed to maximize both clinical and consumer market penetration, supporting sustained growth as it introduces its probiotic solutions.Kamui Pharma, Inc. plans to utilize the funds raised in July 2022 to support new business initiatives and accelerate the development of its drug discovery pipeline. The company is focused on designing and launching new probiotic products, with specific details on release dates pending. Kamui Pharma aims to expand its market presence beyond Japan, targeting selected international markets as partnerships and regulatory approvals are established.

## Funding rounds

- Series B, Jul 26, 2022, $4.8M — Hokkaido Venture Capital, Mitsubishi UFJ Capital, CEJ Capital, DG Incubation
- Series A, May 16, 2018, $2M — Hokkaido Venture Capital, Mitsubishi UFJ Capital

## Investors

- Hokkaido Venture Capital (https://capitalatlas.ai/funds/hokkaido-venture-capital) — Series A, Series B
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series A, Series B
- CEJ Capital (https://capitalatlas.ai/funds/cej-capital) — Series B
- DG Incubation (https://capitalatlas.ai/funds/dg-incubation) — Series B